PT - JOURNAL ARTICLE AU - Henrik Ljungberg AU - Anna Carleborg AU - Hilmar Gerber AU - Christina Öfverström AU - Jakob Wolodarski AU - Faiza Menshi AU - Mikaela Engdahl AU - Marianne Eduards AU - Björn Nordlund TI - Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial AID - 10.1183/13993003.00983-2019 DP - 2019 Jan 01 TA - European Respiratory Journal PG - 1900983 4099 - http://erj.ersjournals.com/content/early/2019/08/14/13993003.00983-2019.short 4100 - http://erj.ersjournals.com/content/early/2019/08/14/13993003.00983-2019.full AB - Background AsthmaTuner is a novel self-management system consisting of a patient app, a cloud-based storage solution and a healthcare interface. Patients use Bluetooth spirometers to measure lung function (FEV1) and can register symptoms. They then receive immediate feedback on asthma control and an image of the correct inhaler(s) to use and the dose. The aim of this pilot study was to evaluate the effect of AsthmaTuner on symptom control and adherence compared with conventional treatment.Material and Methods This multi-centre, physician-blinded, crossover trial, randomised patients in two groups that started with 8 weeks of AsthmaTuner or conventional treatment using printed personalised treatment plans, and 2 weeks of wash-out between the crossover treatments. Participants in a primary or paediatric care setting in Sweden with asthma diagnosis, uncontrolled symptoms and Asthma Control Test (ACT)<20 points were included. Symptom control was analysed using t-tests for the difference between the group means of the sums of ACT at each treatment end-visit, with 95% confidence intervals. Medical Adherence Report Scale scores captured differences in adherence (remembering to take asthma medication) between treatment periods.Results The study population consisted of 77 patients (60% females). The ACT significantly improved with AsthmaTuner compared with conventional treatment (mean 0.70 [0.06–1.34], p=0.03). Adherence did not improve significantly in all participants, but did improve among those in primary care who used AsthmaTuner an average of once a week or more, compared with conventional treatment (mean 0.45 [0.13–0.77], p=0.01).Conclusions AsthmaTuner improved symptom control in patients with uncontrolled asthma.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Ljungberg reports and Henrik Ljungberg is a co-founder and holds shares in the company Medituner that owns Asthmatuner.Conflict of interest: Dr. Carleborg reports personal fees from Medituner AB, outside the submitted work; and I have warrants in the company Medituner.Conflict of interest: Dr. Gerber has nothing to disclose.Conflict of interest: Dr. Öfverström has nothing to disclose.Conflict of interest: Dr. Wolodarski has nothing to disclose.Conflict of interest: Dr. Menshi has nothing to disclose.Conflict of interest: Dr. Engdahl RN has nothing to disclose.Conflict of interest: Dr. Eduards has nothing to disclose.Conflict of interest: Dr. Nordlund reports; B. Nordlund is a co-founder and holds shares in the company Medituner that owns Asthmatuner.